You haven't added any notes for this stock yet. Use this space to record your insights or strategies.
Profile
Healthcare
Sector
Biotechnology
Industry
Dr. David Hallett Ph.D.
CEO
483
Employees
Oxford
Headquarters
GB
Country
Exscientia plc (EXAI) is a global pharmaceutical company specializing in the application of artificial intelligence (AI) and machine learning in drug discovery. The company utilizes advanced AI and bioinformatics technologies for rapid and efficient drug design. By leveraging its innovative methods, Exscientia can explore vast amounts of data and identify potential drug compounds with a high likelihood of success. This accelerates the drug development process and reduces the costs and risks associated with traditional pharmaceutical research. Exscientia collaborates with pharmaceutical companies and research organizations to discover new drugs and develop therapies for various diseases. Its technological innovations and vision for digital drug discovery position it as a leader in AI within the pharmaceutical industry. Exscientia plc (EXAI) shares are publicly traded on the stock exchange and may be attractive to investors interested in innovative technologies in pharmaceutical research.
Key Metrics TTM
Performance
Performance data currently unavailable.
Earnings Waterfall
Debt level and coverage
Earnings
Feed
There are no posts to show right now.
We use cookies to improve your experience on our site.
